OccuRx

OccuRx is an Australian biopharmaceutical company based in Melbourne, founded in 2014.

The company specializes in developing precision therapies aimed at treating inflammatory and fibrotic diseases, particularly through the inhibition of GPR68. OccuRx focuses on identifying novel targets to prevent fibrosis, which can lead to disease progression and organ failure, using biomarkers and genetic analysis to inform its pipeline. The company's leading product is OCX063, a first-in-class oral drug candidate that has completed Phase 1 clinical trials. This therapy is designed to prevent abnormal blood vessel growth and reduce inflammation in conditions such as focal segmental glomerulosclerosis (FSGS) and other fibrotic diseases affecting the kidneys and eyes. OccuRx also has a broader pipeline targeting GPR68 for various conditions, including scleroderma and chronic kidney disease. The company has developed investigational drugs and therapeutic strategies for the healthcare and pharmaceutical industries, emphasizing the role of fibrosis in disease pathology.